ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2018
Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells.
Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Modeling pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease and therapeutic drug screening using hESC-derived mature polarized hepatocyte organoids.Stem cell research & therapy · 2025Article
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Hormone correction of dysfunctional metabolic gene expression in stem cell-derived liver tissue.Stem cell research & therapy · 2025Article
- Association Between Active DNA Demethylation and Liver Fibrosis in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD).International journal of molecular sciences · 2025Article
- Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease.Cell death & disease · 2025Article
- A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver.Cell reports. Medicine · 2024Article
- Organoid-guided precision hepatology for metabolic liver disease.Journal of hepatology · 2024Review
- Effect of Donor Age and Liver Steatosis on Potential of Decellularized Liver Matrices to be used as a Platform for iPSC-Hepatocyte Culture.Advanced healthcare materials · 2024Article
- Review
- The Values and Perspectives of Organoids in the Field of Metabolic Syndrome.International journal of molecular sciences · 2023Review
- Customized liver organoids as an advancedInternational journal of biological sciences · 2023Review
- Advancements in MAFLD Modeling with Human Cell and Organoid Models.International journal of molecular sciences · 2022Review
- Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids.Journal of molecular medicine (Berlin, Germany) · 2022Article
- Review
- Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models.Antioxidants (Basel, Switzerland) · 2021Review
- Genetics Is of the Essence to Face NAFLD.Biomedicines · 2021Review
- Modeling human hepatic steatosis in pluripotent stem cell-derived hepatocytes.STAR protocols · 2021Article
- A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis.iScience · 2021Article
- Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis.Physiological reports · 2020Article
- DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease.International journal of environmental research and public health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in developed countries. An
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.